Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 2/20 | 0.37 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | NOS1 | P29475 | 2/20 | 0.30 |
| ▸ | NOS3 | P29474 | 1/20 | 0.30 |
| ▸ | NOS2 | P35228 | 1/20 | 0.30 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1689113 | 0.80 | GRIK1 (0.39) | GRIK1GRIK2CTSKNOS1NOS3 | |
| SCHEMBL24591259 | 0.80 | GRIK1 (0.39) | GRIK1GRIK2CTSKNOS1NOS3 | |
| SCHEMBL16387589 | 0.79 | CTSK (0.43) | CTSKCA1CA2CA7 | |
| SCHEMBL6334845 | 0.78 | CYP2D6 (0.39) | GRIK1GRIK2KMT2ACTSKMEN1 | |
| SCHEMBL6334844 | 0.78 | CYP2D6 (0.39) | GRIK1GRIK2KMT2ACTSKMEN1 | |
| SCHEMBL4658599 | 0.77 | GRIK1 (0.33) | GRIK1GRIK2CTSKNOS1NOS3 | |
| SCHEMBL7467477 | 0.77 | GRIK1 (0.44) | GRIK1GRIK2KMT2ACTSKMEN1 | |
| SCHEMBL6336899 | 0.77 | GRIK1 (0.44) | GRIK1GRIK2KMT2ACTSKMEN1 | |
| SCHEMBL20184104 | 0.76 | CYP1A2 (0.35) | KMT2AMEN1LMNA | |
| SCHEMBL7854706 | 0.76 | CA1 (0.42) | GRIK1GRIK2KMT2ACA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6607868-B2 | Dipropargyl acetamide | HYNIX SEMICONDUCTOR INC. (KR) | 2003-08-19 | — | — | US | disclosed |
| US-20020012879-A1 | Novel photoresist monomers, polymers thereof, and photoresist compositions containing the same | HYNIX SEMICONDUCTOR INC. (KR) | 2002-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020012879-A1 | Novel photoresist monomers, polymers thereof, and photoresist compositions containing the same | CDH1, DDAH1, DPEP1 | GRIK1 631/4885GRIK2 1509/4885KMT2A 328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.